A study identifies senolytic compounds that can inhibit specific brain enzymes associated with Alzheimer’s disease (AD) while ...

Guidelines are urgently needed on the judicious use of cholinergic drugs. Cholinesterase inhibitors remain pivotal to the treatment of Alzheimer disease (AD), but no specific guidelines are ...

Several clinical trials, some of which remain unpublished, have attempted to determine whether treatment with cholinesterase inhibitors (ChEIs) can slow or prevent the conversion of MCI to ...

In nearly 20 years, aside from cholinesterase inhibitors, memantine is the only drug approved for the treatment of Alzheimer's disease (AD). Memantine is an uncompetitive N-methyl-D-aspartate ...

HC Wainwright initiated coverage on Alpha Cognition, noting a new twist on a tried-and-tested treatment paradigm.

It sees advancements with new drug classes like cholinesterase inhibitors. The global Alzheimer's disease therapeutics market size is projected to expand by $5.41b from 2024-2028 with an estimated ...

Combination therapy uses both cholinesterase inhibitors and NMDA receptor antagonists. Research suggests combination therapy is more effective than monotherapy (single medication use). Combination ...

Galantamine (as HBr) 8mg, 16mg, 24mg; ext-rel caps. Galantamine, a tertiary alkaloid, is a competitive and reversible inhibitor of acetylcholinesterase. While the precise mechanism of galantamine ...